Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922 · Completed

Last updated 2026-05-28

This clinical trial tested the effect and safety of the medication liraglutide 3.0 mg in adults who have overweight or obesity along with type 2 diabetes and are already using basal insulin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 396 people

Who can join Ages 18+ · all sexes

Timeline Started 2017-02 · est. completion 2018-09

Where 54 sites · Canada, Germany, Israel, Italy, Mexico, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT02963922 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.

Treatments tested

Liraglutide 3.0 mg Drug

Injected subcutaneously (s.c., under the skin) once daily
Placebo Drug

Injected subcutaneously (s.c., under the skin) once daily

Main thing measured	Change in Body Weight (%)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02963922 ↗